Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04862286
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-06-17
First Post:
2021-04-26
Brief Title:
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous SC Injection of Risankizumab Who Have Completed Participation in Study M19-977
Sponsor:
AbbVie
Organization:
AbbVie
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-24
Start Date Type:
ACTUAL
Primary Completion Date:
2029-02-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-02-05
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-26
First Submit QC Date:
April 26 2021
Study First Post Date:
2021-04-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-14
Last Update Post Date:
2024-06-17
Last Update Post Date Type:
ACTUAL